Skip to main content
. 2018 Feb 13;118(6):793–801. doi: 10.1038/bjc.2017.495

Table 2. Drug-related AEs ⩾grade 3a.

Related adverse event (preferred term) (no. of events) MK1200+ GEM800 (n=6) Dose level 1 MK1200+ GEM1000 (n=3) Dose level 2a MK1500+ GEM800 (n=3) Dose level 2b MK1500+ GEM1000 (n=4) Dose level 3a MK1800+ GEM800 (n=3) Dose level 3b MK1800+ GEM1000 (n=7) Dose level 4a MK2100+ GEM800 (n=3) Dose level 4b MK2400 (n=1) Dose level 5b
Any ⩾G3 AE 8 6 2 2 11 11 10 1
Anaemia 2 1 1 1 1 2 2  
Lymphocytes decreased   1         1  
Neutropenia     1     4 1  
Thrombocytopenia 1              
WBC decreased           1    
Diarrhoea             1  
Dysphagia         1      
Nausea         1 1    
Vomiting         2      
Fatigue   1         1  
ALT increased         3   1  
AST increased         1 1    
Alk Phos increased         1      
Bilirubin increased 2       1      
Hypokalaemia           1 2 1
Hypophosphatemia   3   1   1 1  
DIC 1              
Intracranial haemorrhage 1              
Debility 1              

Abbreviations: AE=adverse events; Alk Phos=Alkaline Phosphatase; ALT=alanine amino-transferase; AST=aspartate amino-transferase; DIC=disseminated intravascular coagulation; WBC=white blood cells.

a

Only patients that experienced a ⩾grade 3 adverse event are recorded in this table (n=30 out of 44 patients).